215 related articles for article (PubMed ID: 36003403)
21. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
23. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
24. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Wang D; Yang X; Long J; Lin J; Mao J; Xie F; Wang Y; Wang Y; Xun Z; Bai Y; Yang X; Guan M; Pan J; Seery S; Sang X; Zhao H
Front Oncol; 2021; 11():646979. PubMed ID: 33912461
[TBL] [Abstract][Full Text] [Related]
25. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
27. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
28. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
30. Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study.
Wang J; Gao S; Yang Y; Liu X; Zhang P; Dong S; Wang X; Yao W
Cancer Manag Res; 2021; 13():8999-9005. PubMed ID: 34887682
[TBL] [Abstract][Full Text] [Related]
31. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
Cheng H; Zong L; Kong Y; Wang X; Gu Y; Cang W; Zhao J; Wan X; Yang J; Xiang Y
Lancet Oncol; 2021 Nov; 22(11):1609-1617. PubMed ID: 34624252
[TBL] [Abstract][Full Text] [Related]
32. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
Ma N; Qiao H; Tao H; Gan X; Shan Z; Chen X; Zhou X
Clin Res Hepatol Gastroenterol; 2022; 46(7):101962. PubMed ID: 35636681
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis.
Ji X; Liang W; Lv G; Ding C; Lai H; Li L; Zeng Q; Lv B; Sheng L
Front Pharmacol; 2022; 13():933648. PubMed ID: 36091770
[No Abstract] [Full Text] [Related]
34. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
[TBL] [Abstract][Full Text] [Related]
35. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
36. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors - a single Brazilian center experience.
Treistman N; Nobre GM; Tramontin MY; da Silva GMW; Herchenhorn D; de Lima Araujo LH; de Andrade FA; Corbo R; Bulzico D; Vaisman F
Arch Endocrinol Metab; 2021 Nov; 65(4):411-420. PubMed ID: 33939907
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S; Zhao Y; Zhao Y; Wang G
Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
[TBL] [Abstract][Full Text] [Related]
39. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
[No Abstract] [Full Text] [Related]
40. FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177 Lu-FAPI-46.
Fu H; Huang J; Sun L; Wu H; Chen H
Clin Nucl Med; 2022 Oct; 47(10):906-907. PubMed ID: 35485857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
